{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:35:17Z","timestamp":1790508917721,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Low mutation load is associated with a benefit from rituximab maintenance. The Teff signature correlates with high mutation load, is prognostic, and may distinguish immunologically distinct FL subgroups.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016000786","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T00:40:18Z","timestamp":1506559218000},"page":"1884-1890","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":56,"title":["Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets"],"prefix":"10.1182","volume":"1","author":[{"given":"Christopher R.","family":"Bolen","sequence":"first","affiliation":[{"name":"Bioinformatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"McCord","sequence":"additional","affiliation":[{"name":"Oncology Biomarker Development, Genentech, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huet","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Lyon-Sud Hospital Center, Pierre-Benite, France;"},{"name":"Cancer Research Center of Lyon, INSERM U1052, Unit\u00e9 Mixte de Recherche Centre National de la Recherche Scientifique 5286, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bourgon","sequence":"additional","affiliation":[{"name":"Bioinformatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"Henri Becquerel Center, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Dartigues","sequence":"additional","affiliation":[{"name":"Gustave Roussy Institute, Villejuif, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Punnoose","sequence":"additional","affiliation":[{"name":"Oncology Biomarker Development, Genentech, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[{"name":"Oncology Biomarker Development, Genentech, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"Department of Bio-Pathology, Hematology, and Tumor Immunology, and"},{"name":"Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sujobert","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Lyon-Sud Hospital Center, Pierre-Benite, France;"},{"name":"Cancer Research Center of Lyon, INSERM U1052, Unit\u00e9 Mixte de Recherche Centre National de la Recherche Scientifique 5286, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology, Lyon-Sud Hospital Center, Pierre-Benite, France;"},{"name":"Cancer Research Center of Lyon, INSERM U1052, Unit\u00e9 Mixte de Recherche Centre National de la Recherche Scientifique 5286, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Venstrom","sequence":"additional","affiliation":[{"name":"Oncology Biomarker Development, Genentech, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,9,27]]},"reference":[{"issue":"1-2","key":"2019111606592742800_B1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"6230","key":"2019111606592742800_B2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"6230","key":"2019111606592742800_B3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"7471","key":"2019111606592742800_B4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"23","key":"2019111606592742800_B5","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"10031","key":"2019111606592742800_B6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"2019111606592742800_B7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10030","key":"2019111606592742800_B8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"7528","key":"2019111606592742800_B9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"21","key":"2019111606592742800_B10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111606592742800_B11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/2326-6066.CIR-13-0158","article-title":"CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells","volume":"2","author":"Du","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"2019111606592742800_B12","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","article-title":"Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study","volume":"118","author":"Laurent","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111606592742800_B13","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2019111606592742800_B14","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111606592742800_B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9759","key":"2019111606592742800_B16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"2019111606592742800_B17","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"issue":"33","key":"2019111606592742800_B18","doi-asserted-by":"crossref","first-page":"34221","DOI":"10.18632\/oncotarget.5950","article-title":"Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice","volume":"6","author":"Campesato","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"2019111606592742800_B19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2019111606592742800_B20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"5","key":"2019111606592742800_B21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"issue":"2","key":"2019111606592742800_B22","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"2019111606592742800_B23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat Med"},{"issue":"13","key":"2019111606592742800_B24","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7463","key":"2019111606592742800_B25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"2","key":"2019111606592742800_B26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"2019111606592742800_B27","first-page":"128","article-title":"Rituximab treatment circumvents the prognostic impact of tumor infiltrating T-cells in follicular lymphoma patients","volume-title":"Hum Pathol","author":"Xerri","year":"2017"},{"issue":"200","key":"2019111606592742800_B28","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"2019111606592742800_B29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2014-07-592162","article-title":"Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma","volume":"125","author":"Kolstad","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111606592742800_B30","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.93.20.10972","article-title":"Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte\/macrophage colony-stimulating factor primes mice for a protective T-cell response","volume":"93","author":"Kwak","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"2019111606592742800_B31","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","article-title":"Attenuation of CD8+ T-cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"issue":"7528","key":"2019111606592742800_B32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2019111606592742800_B33","first-page":"2253","article-title":"Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin\u2019s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response","author":"Gluck","year":"2004"},{"issue":"21","key":"2019111606592742800_B34","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111606592742800_B35","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2004-03-0859","article-title":"Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells","volume":"104","author":"Grossman","year":"2004","journal-title":"Blood"},{"issue":"7637","key":"2019111606592742800_B36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"6280","key":"2019111606592742800_B37","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"7614","key":"2019111606592742800_B38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature18945","article-title":"Neoantigen landscape dynamics during human melanoma-T cell interactions","volume":"536","author":"Verdegaal","year":"2016","journal-title":"Nature"},{"issue":"16","key":"2019111606592742800_B39","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/22\/1884\/877702\/advances000786.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/22\/1884\/877702\/advances000786.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T11:59:43Z","timestamp":1573905583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/22\/1884\/15686\/Mutation-load-and-an-effector-Tcell-gene-signature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,27]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016000786","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,27]]}}}